Search

Lithium carbonate

Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. … Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843].

Thiocolchicoside

It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663]

OAV201

It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661] … OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter

Clopamide

Like thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.

Ethynodiol diacetate

Although etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug

Flecainide

[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875] … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

Omidenepag isopropyl

[A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients … Omidenepag isopropyl is a topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

ZD4407

It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

Fucoxanthin

, but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. … Fucoxanthin regulates lipids metabolism, the effect most likely mediated by AMK-activated protein kinase. A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing.

Potassium acetate